Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-129968 crossover study in mild to moderate allergic asthma
2008-001209-41Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setipiprant in allergic asthma (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Effect of ACT-129968 versus placebo on FEV1 during the late allergic reaction. Started May 2008; status: completed.
02
Drugs
setipiprant
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2008-001209-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001209-41.